Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma

Oncogene volume 23, pages 8785–8795 (2004)Cite this article

Abstract

Rhabdomyosarcoma (RMS) is a highly malignant tumor that is histologically related to skeletal muscle, yet genetic and molecular lesions underlying its genesis and progression remain largely unknown. In this study we have compared the molecular profiles of two different mouse models of RMS, each associated with a defined primary genetic defect known to play a role in rhabdomyosarcomagenesis in man. We report that RMS of heterozygous Patched1 (Ptch1) mice show less aggressive growth and a greater degree of differentiation than RMS of heterozygous p53 mice. By means of cDNA microarray analysis we demonstrate that RMS in Ptch1 mutants predominantly express a number of myogenic markers, including myogenic differentiation 1, myosin heavy chain, actin, troponin and tropomyosin, as well as genes associated with Hedgehog/Patched signaling like insulin-like growth factor 2, forkhead box gene Foxf1 and the growth arrest and DNA-damage-inducible gene Gadd45a. In sharp contrast, RMS in p53 mutants display higher expression levels of cell cycle-associated genes like cyclin B1, cyclin-dependent kinase 4 and the proliferation marker Ki-67. These results demonstrate that different causative mutations lead to distinct gene expression profiles in RMS, which appear to reflect their different biological characteristics. Our results provide a first step towards a molecular classification of different forms of RMS. If the described differences can be confirmed in human RMS our results will contribute to a new molecular taxonomy of this cancer, which will be critical for gene mutation- and expression-specific therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E and Patel K . (2002). Dev. Biol., 243, 115–127.

  • Armand AS, Della Gaspera B, Launay T, Charbonnier F, Gallien CL and Chanoine C . (2003). Dev. Dyn., 227, 256–265.

  • Astolfi A, De Giovanni C, Landuzzi L, Nicoletti G, Ricci C, Croci S, Scopece L, Nanni P and Lollini PL . (2001). Gene, 274, 139–149.

  • Boman F, Brel D, Antunes L, Alhamany Z, Floquet J and Boccon-Gibod L . (1997). Pediatr. Pathol. Lab. Med., 17, 233–247.

  • Calzada-Wack J, Kappler R, Schnitzbauer U, Richter T, Nathrath M, Rosemann M, Wagner SN, Hein R and Hahn H . (2002). Carcinogenesis, 23, 727–733.

  • Chalaux E, Lopez-Rovira T, Rosa JL, Bartrons R and Ventura F . (1998). J. Biol. Chem., 273, 537–543.

  • Chen X, Raab G, Deutsch U, Zhang J, Ezzell RM and Klagsbrun M . (1995). J. Biol. Chem., 270, 18285–18294.

  • Coindre JM . (2003). Histopathology, 43, 1–16.

  • Couet J, Belanger MM, Roussel E and Drolet MC . (2001). Adv. Drug. Deliv. Rev., 49, 223–235.

  • Dagher R and Helman L . (1999). Oncologist, 4, 34–44.

  • Davis RJ, D’Cruz CM, Lovell MA, Biegel JA and Barr FG . (1994). Cancer Res., 54, 2869–2872.

  • Doyle DD, Upshaw-Earley J, Bell E and Palfrey HC . (2003). Biochem. Biophys. Res. Commun., 304, 22–25.

  • Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ and Helman LJ . (1992). Cancer Res., 52, 2243–2247.

  • Fleischmann A, Jochum W, Eferl R, Witowsky J and Wagner EF . (2003). Cancer Cell, 4, 477–482.

  • Gorlin RJ . (1987). Medicine (Baltimore), 66, 98–113.

  • Hahn H, Wojnowski L, Specht K, Kappler R, Calzada-Wack J, Potter D, Zimmer A, Muller U, Samson E and Quintanilla-Martinez L . (2000). J. Biol. Chem., 275, 28341–28344.

  • Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G and Zimmer A . (1998). Nat. Med., 4, 619–622.

  • Harvey M, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A and Donehower LA . (1993). Nat. Genet., 5, 225–229.

  • Horn RC and Enterline HT . (1958). Cancer, 11, 181–199.

  • Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT and Weinberg RA . (1994). Curr. Biol., 4, 1–7.

  • Kablar B, Krastel K, Tajbakhsh S and Rudnicki MA . (2003). Dev. Biol., 258, 307–318.

  • Kappler R, Calzada-Wack J, Schnitzbauer U, Koleva M, Herwig A, Piontek G, Graedler F, Adamski J, Heinzmann U, Schlegel J, Hemmerlein B, Quintanilla-Martinez L and Hahn H . (2003). J. Pathol., 200, 348–356.

  • Kappler R, Heß I, Schlegel J and Hahn H . (2004). Int. J. Oncol., 25, 113–120.

  • Karpen HE, Bukowski JT, Hughes T, Gratton JP, Sessa WC and Gailani MR . (2001). J. Biol. Chem., 276, 19503–19511.

  • Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fournier JG, Verdiere-Sahuque M, Fardeau M and Alameddine HS . (1999). Dev. Biol., 205, 158–170.

  • Lagutina I, Conway SJ, Sublett J and Grosveld GC . (2002). Mol. Cell. Biol., 22, 7204–7216.

  • Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA and Friend SH . (1990). Science, 250, 1233–1238.

  • May P and May E . (1999). Oncogene, 18, 7621–7636.

  • Merlino G and Helman LJ . (1999). Oncogene, 18, 5340–5348.

  • Moretti A, Borriello A, Monno F, Criscuolo M, Rosolen A, Esposito G, Dello Iacovo R, Della Ragione F and Iolascon A . (2002). Eur. J. Cancer, 38, 2290–2299.

  • Mulligan LM, Matlashewski GJ, Scrable HJ and Cavenee WK . (1990). Proc. Natl. Acad. Sci. USA, 87, 5863–5867.

  • Ragazzini P, Gamberi G, Pazzaglia L, Serra M, Magagnoli G, Ponticelli F, Ferrari C, Ghinelli C, Alberghini M, Bertoni F, Picci P and Benassi MS . (2004). Histol. Histopathol., 19, 401–411.

  • Ruiz i Altaba A, Sanchez P and Dahmane N . (2002). Nat. Rev. Cancer, 2, 361–372.

  • Scrable HJ, Witte DP, Lampkin BC and Cavenee WK . (1987). Nature, 329, 645–647.

  • Shapiro DN, Sublett JE, Li B, Downing JR and Naeve CW . (1993). Cancer Res., 53, 5108–5112.

  • Shen X, Collier JM, Hlaing M, Zhang L, Delshad EH, Bristow J and Bernstein HS . (2003). Dev. Dyn., 226, 128–138.

  • Stratton MR, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher CD, Ball A, Thomas M, Gusterson BA and Cooper MK . (1990). Oncogene, 5, 1297–1301.

  • Sun FL, Dean WL, Kelsey G, Allen ND and Reik W . (1997). Nature, 389, 809–815.

  • Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP and Beachy PA . (2000). Nature, 406, 1005–1009.

  • Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D and Donehower LA . (1998). EMBO J., 17, 4657–4667.

  • Wada MR, Inagawa-Ogashiwa M, Shimizu S, Yasumoto S and Hashimoto N . (2002). Development, 129, 2987–2995.

  • Wetmore C, Eberhart DE and Curran T . (2001). Cancer Res., 61, 513–516.

  • Wexler LH and Helman LJ . (1997). Rhabdomyosarcoma and the Undifferentiated Sarcomas, 3rd edn. Raven-Lippincott: Philadelphia.

    Google Scholar 

  • Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL and Wang FY . (2003). Proc. Natl. Acad. Sci. USA, 100, 4616–4621.

  • Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T and Hoffman AR . (2003). J. Clin. Invest., 111, 265–273.

  • Zhan S, Shapiro DN and Helman LJ . (1994). J. Clin. Invest., 94, 445–448.

Download references

Acknowledgements

We are grateful to Elenore Samson and Jaqueline Müller for excellent animal care as well as Ina Heß, Astrid Herwig, Milena Koleva and Paul Thelen for technical assistance. We thank Leszek Wojnowski, Jack Favor and Mike Atkinson for helpful comments on the manuscript. This work was supported by a BioFuture-Grant of the German Ministry for Education and Research BMBF (to HH).

Author information

Authors and Affiliations

  1. Institute of Human Genetics, University of Göttingen, Heinrich-Düker-Weg 12, Göttingen, Germany

    Roland Kappler, Regine Bauer & Heidi Hahn

  2. Institute of Pathology, GSF-National Research Center for Environment and Health, Neuherberg, Germany

    Julia Calzada-Wack & Michael Rosemann

  3. Department of Pathology, University of Göttingen, Göttingen, Germany

    Bernhard Hemmerlein

Authors
  1. Roland Kappler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Regine Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julia Calzada-Wack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Rosemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernhard Hemmerlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heidi Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heidi Hahn.

Additional information

Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kappler, R., Bauer, R., Calzada-Wack, J. et al. Profiling the molecular difference between Patched- and p53-dependent rhabdomyosarcoma. Oncogene 23, 8785–8795 (2004). https://doi.org/10.1038/sj.onc.1208133

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208133

Keywords

This article is cited by

Search

Advanced search

Quick links